NIT
CRSP icon

NumerixS Investment Technologies’s CRISPR Therapeutics CRSP Stock Holding History

NumerixS Investment Technologies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,206
Closed -$51K – 1107
2020
Q1 		$51K Sell
1,206
-26,189
-96% -$1.35M 0.03% 601
2019
Q4 		$1.67M Buy
27,395
+25,695
+1,511% +$1.4M 0.33% 58
2019
Q3 		$70K Sell
1,700
-1,250
-42% -$59.7K 0.02% 649
2019
Q2 		$139K Buy
2,950
+550
+23% +$22K 0.04% 505
2019
Q1 		$84K Sell
2,400
-2,800
-54% -$96.8K 0.01% 909
2018
Q4 		$139K Sell
5,200
-1,600
-24% -$55.6K 0.04% 458
2018
Q3 		$316K Buy
+6,800
New +$356K 0.06% 427

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

NumerixS Investment Technologies's CRSP Position: Q2 2020 in Review

NumerixS Investment Technologies sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 1,206 shares — an estimated $51K sold.

NumerixS Investment Technologies first reported a position in CRSP in Q3 2018 and held it in 7 quarters. The position peaked at $1.67M in Q4 2019. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • NumerixS Investment Technologies reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 1,206 CRISPR Therapeutics shares in Q2 2020, an estimated $51K.
  • NumerixS Investment Technologies first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 7 quarters.
  • NumerixS Investment Technologies's CRISPR Therapeutics position peaked at $1.67M in Q4 2019.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on NumerixS Investment Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.